Pathology of preinvasive and excellent-prognosis breast cancer

Current Opinion in Oncology

Volumn 9, Issue 6, 1997, Pages 512-519

  Simpson, Jean F ^a   Page, David L ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HORMONE RECEPTOR;

BREAST BIOPSY; BREAST CANCER; BREAST CARCINOMA; BREAST DUCT; BREAST HYPERPLASIA; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CARCINOMA IN SITU; ECHOMAMMOGRAPHY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MAMMOGRAPHY; METASTASIS POTENTIAL; NEEDLE BIOPSY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TUMOR BIOPSY;

EID: 0030838180     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199711000-00004     Document Type: Review

References (64)

1. Marshall LM, Hunter DJ, Connolly JL, Schnitt SJ, Byrne C, London SJ, Colditz GA: Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. Cancer Epidemiol Biomarkers Prev 1997, 6:297-301. This is the fifth major paper validating the cancer risk implications of specifically defined histopathologic patterns of atypical hyperplasia designated lobular and ductal patterns. The magnitude of risk for the lobular lesions in the premenopausal group appears to be higher, losing much of its magnitude after the menopause.
2. London SJ, Connolly JL, Schnitt SJ, Colditz GA: A prospective study of benign breast disease and the risk of breast cancer. JAMA 1992, 267:941-944.
3. Dupont WD, Page DL: Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985, 312:146-151.
4. Bodian CA, Perzin KH, Lattes R: Lobular neoplasia: long term risk of breast cancer and relation to other factors. Cancer 1996, 78:1024-1034. Associations with additive and subtractive risk implications in lobular neoplasia are evaluated; eg, family history continues to have a somewhat additive factor to risk in this group of lesions.
5. Page DL, Kidd TEJ, Dupont WD, Simpson JF, Rogers LW: Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. Hum Pathol 1991, 22:1232-1239.
6. Fisher ER, Costantino J, Fisher B, Palekar AS, Paik SM, Suarez CM, Wolmark N, and National Surgical Adjuvant Breast and Bowel Project Collaborating Investigators: Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17: five-year observations concerning lobular carcinoma in situ. Cancer 1996, 78:1403-1416. This represents the first careful attempt to evaluate lesions with combined features of DCIS and LCIS. More minimal histopathologic examples of the lobular series lesions are also shown to have lesser cancer risk implications.
7. Souvinos G, Kiaris H, Tsikkinis A, Vassilaros S, Spandidos DA: Microsatellite instability and loss of heterozygosity in primary breast tumours. Tumour Biol 1997, 18:157-166. Several foci of genetic alteration in breast cancer are identified, validating many previously identified as associated with breast cancer.
8. Rosenberg CL, Larson PS, Romo JD, de las Morenas A, Faller DV: Microsatellite alterations indicating monoclonality in atypical hyperplasias associated with breast cancer. Hum Pathol 1997, 28:214-219.
9. Lakhani SR, Slack DN, Hamoudi RA, Collins N, Stratton MR, Sloane JP: Detection of allelic imbalance indicates that a proportion of mammary hyperplasia of usual type are clonal neoplastic proliferations. Lab Invest 1996, 74:129-135. Rarely, genetic alterations may be identified in hyperplastic lesions of the breast without atypical anatomic features. The practical implications of this finding remain unknown.
10. Kasami M, Vnencak-Jones CL, Manning S, Dupont WD, Page DL: Loss of heterozygosity and microsatellite instability in breast hyperplasia: no obligate correlation of these genetic alterations with subsequent malignancy. Am J Pathol 1997, 150:1925-1932. Multiple genetic alterations may be found in hyperplastic lesions with atypia; such lesions are quite uncommon without anatomic features of atypia, and even when many are present they may have no implications in an individual patient for the later development of malignancy.
11. Nayar R, Zhuang Z, Merino MJ, Silverberg SG: Loss of heterozygosity on chromosome 11q13 in lobular lesions of the breast using tissue microdissection and polymerase chain reaction. Hum Pathol 1997, 28:277-282.
12. Chuaqui RF, Zhuang Z, Emmert-Buck MR, Liotta LA, Merino MJ: Analysis of loss of heterozygosity on chromosome 11q13 in atypical ductal hyperplasia and in situ carcinoma of the breast. Am J Pathol 1997, 150:297-303.
13. Simpson JF, Quan DE, O'Malley FP, Odom-Maryon T, Clarke PE: Amplification of CCND1 and expression of its protein product, cyclin D1, in ductal carcinoma in situ of the breast. Am J Pathol 1997, 151:161-168. Many basic science papers have indicated the possible importance of cyclin D1 in the control of proliferation of breast carcinomas. This paper is the first to demonstrate a correlation between gene amplification and protein expression in DCIS.
14. Munn KE, Walker RA, Menasce L, Varley JM: Mutation of the TP53 gene and allelic imbalance at chromosome 17p13 in ductal carcinoma in situ. Br J Cancer 1996, 74:1578-1585.
15. Chappell S, Walsh T, Walker RA, Shaw JA: Loss of heterozygosity at chromosome 6q in preinvasive and early invasive breast carcinomas. Br J Cancer 1997, 75:1324-1329.
16. Fujii H, Szumel R, Marsh C, Zhou WB, Gabrielson E: Genetic progression, histologic grade, and allelic loss in ductal carcinoma in situ of the breast. Cancer Res 1996, 56:5260-5265.
17. Fujii H, Marsh C, Cairns P, Sidransky D, Gabrielson E: Genetic divergence in the clonal evolution of breast cancer. Cancer Res 1996, 56:1493-1497.
18. Silverstein MJ, Lagios MD, Craig PH: A prognostic index for ductal carcinoma in situ of the breast. Cancer 1996, 77:2267-2274.
19. Scott MA, Lagios MD, Axelsson K, Rogers LW, Anderson TJ, Page DL: Ductal carcinoma in situ of the breast: reproducibility of histological subtype analysis. Hum Pathol 1997, 967-973. This paper reports interobserver reproducibility in a modified Lagios classification for DCIS, which will be the basis of several clinical studies underway on the efficacy of various treatment approaches to DCIS.
20. Lagios MD, Margolin FR, Westdahl PR, Rose MR: Mammographically detected duct carcinoma in situ: frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence. Cancer 1989, 63:618-624.
21. Douglas-Jones AG, Gupta SK, Attanoos RL, Morgan JM, Mansel RE: A critical appraisal of six modern classifications of ductal carcinoma in situ of the breast (DCIS): correlation with grade of associated invasive carcinoma. Histopathology 1996, 29:397-409.
22. Gage I, Schnitt SJ, Nixon AJ, Silver BJ, Recht A, Troyan SL, Eberlein T, Love SM, Gelman RS, Harris JR, Connolly JL: Pathologic margin involvement and the risk of recurrence in patients treated with breast-conserving therapy. Cancer 1997, 78:1921-1928. A further useful addition to a series of papers from this group on the importance of ascertainment of margins in the conserved breast.
23. Guidi AJ, Connolly JL, Harris JR, Schnitt SJ: The relationship between shaved margin and inked margin status in breast excision specimens. Cancer 1997, 79:1568-1573.
24. Solin LJ, Kurtz J, Fourquet A, Amalric R, Recht A, Bornstein BA, Kuske R, Taylor M, Barrett W, Fowble B, et al.: Fifteen-year results of breast-conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast. J Clin Oncol 1997, 14:754-763. Details the experience with radiation treatment for larger and less carefully evaluated lesions of DCIS.
25. Norden T, Thurfjell E, Hasselgren M, Lindgren A, Norgren A, Bergstrom R, Holmberg L: Mammographic screening for breast cancer: what cancers do we find? Eur J Cancer 1997, 33:624-628.
26. Arnesson L-G, Hatschek T, Smeds S, Grontoft O: Histopathology grading in small breast cancers < 10mm: results from an area with mammography screening. Breast Cancer Res Treat 1997, 44:39-46. The combined histologic grade is shown to be of great importance in stratifying small breast cancers with metastatic capacity.
27. Fentiman IS, Hyland D, Chaudary MA, Gregory WM: Prognosis of patients with breast cancers up to 1 cm in diameter. Eur J Cancer 1996, 32:417-420.
28. Lee AKC, Loda M, Mackarem G, Bosari S, DeLellis RA, Heatley GJ, Hughes K: Lymph node negative invasive breast carcinoma 1 centimeter or less in size (T1aN0M0): clinicopathologic features and outcome. Cancer 1996, 78:761-771.
29. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer: the value of histologic grade in breast cancer: experience from a large study with long term follow-up. Histopathology 1991, 19:403-410.
30. Page DL, Anderson TJ, Elston CW: Grading of invasive carcinoma of the breast. In Diagnostic Histopathology of the Breast. Edited by Page DL, Anderson TJ. New York: Churchill-Livingstone; 1987:300-311.
31. Page DL, Gray GF Jr: Pathology of mammographically discovered breast cancer: clinical implications of size and histologic differentiation. Surg Clin North Am 1997, 6:335-342.
32. Barth A, Craig PH, Silverstein MJ: Predictors of axillary lymph node metastases in patients with T1 breast carcinoma. Cancer 1997, 79:1918-1922.
33. De Laurentiis M, Gallo C, De Placido S, Perrone F, Pettinato G, Petrella G, Carlomagno C, Panico L, Delrio P, Bianco AR: A predictive index of axillary nodal involvement in operable breast cancer. Br J Cancer 1996, 73:1241-1247.
34. Chontos AJ, Maher DP, Ratzer ER, Fenoglio ME: Axillary lymph node dissection: is it required in T1a breast cancer? J Am Coll Surg 1997, 184:493-498.
35. Cady B: Use of primary breast carcinoma characteristics to predict lymph node metastases. Cancer 1997, 79:1856-1861.
36. Giuliano AE, Jones RC, Brennan M, Statman R: Sentinel lymphadenectomy in breast cancer. J Clin Oncol 1997, 15:2345-2350. Reports on the current status of sentinel lymphadenectomy in breast cancer. This is a promising and developing area in the management of breast cancers with a low likelihood of nodal involvement.
37. Giuliano AE, Barth A, Spivack B, Beitsch PD, Evans SW: Incidence and predictors of axillary metastasis in T1 carcinoma of the breast. J Am Coll Surg 1996, 183:185-189.
38. Silverstein MJ, Barth A: Use of primary breast carcinoma characteristics to predict lymph node metastases [reply]. Cancer 1997, 79:1862-1864.
39. Noguchi S, Aihara T, Motomura K, Inaji H, Imaoka S, Koyama H: Histologic characteristics of breast cancers with occult lymph node metastases detected by keratin 19 mRNA reverse transcriptase chain reaction. Cancer 1996, 78:1235-1240.
40. Schoenfeld A, Luqmani Y, Sinnett HD, Shousha S, Coombes RC: Keratin 19 mRNA measurement to detect micrometastases in lymph nodes in breast cancer patients. Br J Cancer 1996, 74:1639-1642.
41. Gamel JW, Meyer JS, Feuer E, Miller BA: The impact of stage and histology on the long-term clinical course of 163,808 patients with breast carcinoma. Cancer 1996, 77:1459-1464.
42. Bergers E, van Diest PJ, Baak JPA: Cell cycle analysis of 932 flow cytometric DNA histograms of fresh frozen breast carcinoma material: correlations between flow cytometric, clinical, and pathologic variables. Cancer 1996, 77:2258-2266.
43. Hawkins RA, Tesdale AL, Killen ME, Jack WJL, Chetty U, Dixon JM, Hulme MJ, Prescott RJ, McIntyre MA, Miller WR: Prospective evaluation of prognostic factors in operable breast cancer. Br J Cancer 1996, 74:1469-1468.
44. Dettmar P, Harbeck N, Thomssen C, Pache L, Ziffer P, Fizi K, Janicke F, Nathrath W, Schmitt M, Graeff H, Hofler H: Prognostic impact of proliferation-associated factors MIB1 (Ki-67) and S-phase in node-negative breast cancer. Br J Cancer 1997, 75:1525-1533.
45. Todd JH, Dowle CS, Williams MR: Confirmation of prognostic index in primary breast cancer. Br J Cancer 1987, 56:489-492.
46. Galea MH, Blamey RW, Elston CE, Ellis IO: The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 1992, 22:207-219.
47. Sauerbrei W, Hubner K, Schmoor C, Schumacher M, German Breast Cancer Study Group: Validation of existing and development of new prognostic classification schemes in node negative breast cancer. Breast Cancer Res Treat 1997, 42:149-163.
48. Kollias J, Elston CE, Ellis IO, Robertson JFR, Blamey RW: Early-onset breast cancer: histopathological and prognostic considerations. Br J Cancer 1997, 75:1318-1323. In this paper, the better prognosis of breast cancer in older patients is positively correlated with their having lower-grade lesions than younger women.
49. Visscher DW, Sarkar FH, Crissman JD: Molecular genetic analysis in the pathologic evaluation of solid tumors: theory and practice. J Clin Lab Anal 1997, 11:10-16. An excellent review of the various promising and nonpromising areas of genetic analysis in breast cancer.
50. Walker RA, Jones JL, Chappell S, Walsh T, Shaw JA: Molecular pathology of breast cancer and its application to clinical management. Cancer Metastasis Rev 1997, 16:5-27.
51. Moll R, Mitze M, Frixen UH, Birchmeier W: Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas. Am J Pathol 1993, 143:1731-1742.
52. Berx G, Cleton-Jansen A-M, Strumane K, de Leeuw WJF, Nollet F, van Roy F, Cornelisse C: E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene 1996, 13:1919-1925.
53. Devia A, Murray KA, Nelson EW: Stereotactic core needle biopsy and the workup of mammographic breast lesioins. Arch Surg 1997, 132:512-516.
54. Nguyen M, McCombs MM, Ghandehari S, Kim A, Wang H, Barsky SH, Love SM, Bassett LW: An update on core needle biopsy for radiologically detected breast lesions. Cancer 1996, 78:2340-2345.
55. Page DL, Johnson JE, Dupont WD: Probabilistic approach to the reporting of fine-needle aspiration cytology of the breast. Cancer Cytopathol 1997, 81:6-9.
56. Abati A: The uniform approach to breast fine needle aspiration biopsy: a synopsis. Acta Cytol 1996, 40:1120-1126. A report on the utility of FNA cytology when performed by practiced and devoted hands.
57. Liberman L, LaTrenya LR, van Zee KJ, Morris EA, Abramson AF, Dershaw DD: Stereotactic core biopsy of calcifications highly suggestive of malignancy. Radiology 1997, 203:673-677.
58. Ballo MS, Sneige N: Can core biopsy replace fine-needle aspiration cytology in the diagnosis of palpable breast carcinoma: a comparative study of 124 women. Cancer 1996, 78:773-777.
59. Rubenchik I, Sneige N, Edeiken B, Samuels B, Fornage B: In search of specimen adequacy in fine-needle aspirates of nonpalpable breast lesions. Am J Clin Pathol 1997, 108:13-18.
60. Di Loreto C, Puglisi F, Rimondi G, Zuiani C, Anania G, Della Mea V, Beltrami CA: Large core biopsy for diagnostic and prognostic evaluation of invasive breast carcinomas. Eur J Cancer 1996, 32:1693-1700.
61. Alberts SR, Ingle JN, Roche PR, Cha SS, Wold LE, Farr GHJ, Krook JE, Wieand HS: Comparison of estrogen receptor determinations by a biochemical ligand-binding assay and immunohistochemical staining with monoclonal antibody ER1D5 in females with lymph node positive breast carcinoma entered on two prospective clinical trials. Cancer 1996, 78:764-772.
62. Makris A, Allred DC, Powles TJ, Dowsett M, Fernanco IN, Trott PA, Ashley SE, Ormerod MG, Titley JC, Osborne CK: Cytological evaluation of biological prognostic markers from primary breast carcinomas. Breast Cancer Res Treat 1997, 44:65-74.
63. Nakhleh RE, Jones B, Zarbo RJ: Mammographically directed breast biopsies: a College of American Pathologists Q-Probes study of clinical physician expectations and of specimen handling and reporting characteristics in 434 institutions. Arch Pathol Lab Med 1997, 121:11-18.
64. Niemann TH, Lucas JG, Marsh WLJ: To freeze or not to freeze: a comparison of methods for the handling of breast biopsies with no palpable abnormality. Am J Clin Pathol 1996, 106:225-228.